Heparin Sodium — Class II drug recall D-0434-2023
Terminated recall by B. Braun Medical Inc, reported 2023-03-15, distributed nationwide. Subpotent Drug: low Anti-Factor IIa potency.
| Recall number | D-0434-2023 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Recalling firm | B. Braun Medical Inc, Irvine, CA, United States |
| Recall initiated | 2023-03-01 |
| Classified | 2023-03-06 |
| Reported by FDA | 2023-03-15 |
| Terminated | 2024-03-13 |
| Distributed | Nationwide (US) |
| Quantity | 30,672 |
| Reason classes | potency |
| NDC | 00264-9567, 00264-9567-10, 00264-9577, 00264-9577-10, 00264-9587, 00264-9587-20 |
| Lot numbers | J2C017 |
| Expiration dates | 2023-09-30 |
Product
Heparin Sodium, 25,000USP units per 250 mL, (100 USP units per mL) in 5% Dextrose Injection, 250 mL Excel Container, B.Braun Medical Inc, Bethlehem, PA. 18018-3524 USA. NDC 0264-9587-20.
Reason for recall
Subpotent Drug: low Anti-Factor IIa potency.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0434-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.